Robert G. Kramer sold nearly 90,000 shares of his stock in Emergent BioSolutions, knowing that large quantities of vaccine materials were contaminated, the lawsuit said. By Neil Vigdor and Chris Hamby ...
A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a ...
Hosted on MSN
NY AG sues former Emergent CEO over insider tradingA former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a ...
New York Attorney General Letitia James filed suit against the former head of Emergent BioSolutions EBS1.62%increase; green up pointing triangle, accusing him of insider trading for selling his shares ...
Emergent BioSolutions Inc. (NYSE: EBS) stock rose in Friday premarket trading. On Thursday, New York Attorney General Letitia James sued former chief executive Robert G. Kramer over alleged insider ...
Two years ago, Emergent BioSolutions came to a settlement with shareholders, agreeing to pay $40 million to resolve allegations of wrongdoing by company executives, which included insider trading ...
NEW YORK, Jan 15 (Reuters) - A former chief executive of Emergent BioSolutions (EBS.N), opens new tab was charged on Thursday with insider trading by New York Attorney General Letitia James for ...
The New York attorney general’s office has filed suit against the former CEO of Emergent Biosolutions Inc., alleging insider trading, while at the same time announcing a settlement with the company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results